Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “anti-”

1,068 pharma patents match "anti-" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,068
Index total 30,257
Page 41 / 45

Quick answer

This filtered view shows 1,068 pharmaceutical patents matching "anti-" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,068 results for “anti-” · 30,257 patents in full index Clear search

  1. US 7511124

    Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents

    The Board of Regents of the University of Texas System · Granted Mar 31, 2009 · Expires Mar 26, 2029

    granted

  2. US 7504430

    Maleiimide anti-tumor phosphatase inhibitors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 17, 2009 · Expires Mar 12, 2029

    granted

  3. US 7498353

    Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses

    Rigel Pharmaceuticals, Inc. · Granted Mar 3, 2009 · Expires Feb 26, 2029

    granted

  4. US 7491802

    Anti-BAMBI antibody and diagnostic or remedy for colon cancer and liver cancer

    Takeda Pharmaceutical Company Limited · Granted Feb 17, 2009 · Expires Feb 12, 2029

    granted

  5. US 7482351

    4-pyrimidineamine compounds and their uses as anti-proliferative agents

    Rigel Pharmaceuticals, Inc. · Granted Jan 27, 2009 · Expires Jan 22, 2029

    granted

  6. US 7479484

    Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity

    Takeda Pharmaceutical Company Limited · Granted Jan 20, 2009 · Expires Jan 15, 2029

    granted

  7. US 7476657

    Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments

    Takeda Pharmaceutical Company Limited · Granted Jan 13, 2009 · Expires Jan 8, 2029

    granted

  8. US 7473525

    Compositions and methods for inhibiting expression of anti-apoptotic genes

    Alnylam Europe AG · Granted Jan 6, 2009 · Expires Jan 1, 2029

    granted

  9. US 7470775

    Anti-CD30 stalk and anti-CD30 antibodies suitable for use in immunotoxins

    The United States of America, as represented by the Department of Health and Human Services · Granted Dec 30, 2008 · Expires Dec 25, 2028

    granted

  10. US 7465449

    Anti-αvβ6 antibodies

    The Regents of the University of California · Granted Dec 16, 2008 · Expires Dec 11, 2028

    granted

  11. US 7449182

    Therapeutic combination of a VEGF antagonist and anti-hypertensive agent

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 11, 2008 · Expires Nov 6, 2028

    granted

  12. US 7427496

    Anti-cancer compounds

    The Regents of the University of Colorado · Granted Sep 23, 2008 · Expires Sep 18, 2028

    granted

  13. US 7423142

    Compositions and methods for inhibiting expression of anti-apoptotic genes

    Alnylam Pharmaceuticals, Inc. · Granted Sep 9, 2008 · Expires Sep 4, 2028

    granted

  14. US 7388089

    Anti-arthropod vector vaccines method of selecting and uses thereof

    The United States of America, as represented by the Department of Health and Human Services · Granted Jun 17, 2008 · Expires Jun 12, 2028

    granted

  15. US 7384909

    Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents

    The Board of Regents of the University of Texas System · Granted Jun 10, 2008 · Expires Jun 5, 2028

    granted

  16. US 7378386

    Anti-viral treatment methods using phosphatidylethanolamine-binding peptide derivatives

    The Board of Regents of the University of Texas System · Granted May 27, 2008 · Expires May 22, 2028

    granted

  17. US 7358085

    Anti-angiogenic methods and compositions

    Sangamo Biosciences, Inc. · Granted Apr 15, 2008 · Expires Apr 10, 2028

    granted

  18. US 7355012

    Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted

  19. US 7354581

    Therapeutic combination of a VEGF antagonist and anti-hypertensive agent

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted

  20. US 7354579

    Method of treating cancer with a VEGF antagonist and an anti-proliferative agent

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted

  21. US 7326695

    Anti-bacterial agents based upon oxoanion binding

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Feb 5, 2008 · Expires Jan 31, 2028

    granted

  22. AU 2007271920

    Benzyl amines, a process for their production and their use as anti-inflammatory agents

    BAYER SCHERING PHARMA AG [SE] · Granted Jan 17, 2008 · Expires Jan 12, 2028

    granted

  23. US 7319000

    Compositions and methods for eliciting immune or anti-infective responses

    The Board of Regents of the University of Texas System · Granted Jan 15, 2008 · Expires Jan 10, 2028

    granted

  24. US 7303751

    Anti-plasmodium compositions and methods of use

    The Government of the United States of American, as represented by the Secretary, Department of Health and Human Services · Granted Dec 4, 2007 · Expires Nov 29, 2027

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.